Abstract: A high pressure medical connector tubing assembly includes a high pressure medical connector tubing assembly, including a tube element having opposed tube ends and a passageway, an end element overmolded to at least one of the opposed tube ends, the end element having an annular end portion having a preselected length, and a connector element having a connector hub defining a receiving cavity. The preselected length of the annular end portion may be used to pre-control the axial location of stress concentration in the connector hub. A method of forming the high pressure medical connector tubing assembly includes providing a tube element comprising opposed tube ends and a passageway therethrough, overmolding an end element onto at least one of the opposed tube ends, providing a connector element comprising a connector hub defining a receiving cavity, and securing the tube end with the overmolded end element in the receiving cavity.

Abstract: This invention relates to novel 2,3-dihydroimidazo[1,2-c]quinazoline compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for phosphotidylinositol-3-kinase (PI3K) inhibition and treating diseases associated with phosphotidylinositol-3-kinase (PI3K) activity, in particular treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients.

Abstract: A pressure isolation mechanism including a valve housing which defines a first lumen associated with a pressurizing device, a second lumen associated with an input line which connects a low pressure fluid delivery system to the valve housing, and a pressure isolation port is disclosed. The pressure isolation mechanism further includes a first valve having a normally open position permitting fluid communication between the first lumen and the second lumen and movable to a closed position when fluid pressure in the first lumen reaches a predetermined pressure level, and a second valve disposed within the second lumen and regulating fluid flow through the second lumen, wherein the second valve substantially isolates the input line from a pressure transducer connected to the pressure isolation port. A method for correcting for dampened hemodynamic blood pressure signals in a fluid delivery system which includes the pressure isolation mechanism is also described.

Abstract: An aqueous or powder composition includes anti-gram-negative antibiotic or salt thereof being present at an amount ranging from about 100 mg/ml to about 200 mg/ml. Another aqueous or powder composition includes anti-gram-positive antibiotic or salt thereof being present at a concentration ranging from about 0.6 to about 0.9 of the water solubility limit, at 25° C. and 1.0 atmosphere, of the anti-gram-positive antibiotic or salt thereof. Other embodiments include unit doses, kits, and methods.

Abstract: A system for identifying information regarding a syringe assembly used with a fluid injector includes at least one syringe assembly having a barrel extending from a distal end to an open proximal end, at least one indicator provided on at least a portion of an outer circumferential surface of the barrel, an injector having at least one syringe port adapted to receive the at least one syringe assembly, and at least one sensor provided on or within at least a portion of each syringe port. The at least one indicator may conduct electricity corresponding to information regarding the at least one syringe assembly, which is identified by the at least one sensor.

Abstract: The present invention relates to: use of a 2,3-dihydroimidazo[1,2-c]quinazoline compound, or of a pharmaceutical composition containing same, as a sole active agent, or of a combination of a) said compound or a pharmaceutical composition containing said compound and b) one or more further active agents, for the preparation of a medicament for the treatment or prophylaxis of endometrial cancer (hereinafter abbreviated to “EC”), particularly 1st line, 2nd line, relapsed, refractory, type I or type II EC, or endometriosis; combinations of a) said compound and b) one or more further active agents; a pharmaceutical composition comprising said compound as a sole active agent for the treatment of endometrial cancer (hereinafter abbreviated to “EC”), particularly 1st line, 2nd line, relapsed, refractory, type I or type II EC, or endometriosis; a pharmaceutical composition comprising a combination of a) said compound and b) one or more further active agents; use of biomarkers which is the loss of tumor suppressor PTEN

Abstract: The invention comprises novel pyrazolyl derivatives of the general formula (I) Also described are processes for preparing the compounds of the formula (I). The compounds according to the invention are especially suitable for controlling insects and arachnids in agriculture, and ectoparasites in veterinary medicine.

Abstract: The present invention relates to inhibitors of the Wnt signalling pathways of general formula (I) wherein LA represents *CH2** or *?**; wherein indicates the point of attachment to the carbonyl group, and ** indicates the point of attachment to R1; LB represents *N(H)—C(?O)** or *C(?O)—N(H)**; wherein * indicates the point of attachment to R2, and ** indicates the point of attachment to the phenyl group; R1 represents a group selected from: (AA); wherein * indicates the point of attachment to LA, R2 represents: (BB) wherein * indicates the point of attachment to R3, and ** indicates the point of attachment to LB R3 represents a group selected from: (CC); wherein * indicates the point of attachment to R2; R4 and R5 represent a hydrogen atom; and R6 represents a halogen atom or group selected from: —CH3, —O—CH3, —O—CHF2, —O—CF3, and —O-cyclopropyl; to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing

Abstract: The present invention relates to inhibitors of the Wnt signalling pathways of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative disorder, as a sole agent or in combination with other active ingredients.

Abstract: The present invention describes a novel process for preparing piperidine-4-carbothioamide hydrochloride.

Abstract: What is described are BET protein-inhibitory, in particular BRD4-inhibitory 2,3-benzodiazepines of the general formula (I) in which R1a, R1b, R1c, R2, R3, R4, R5, A and X have the meanings given in the description, intermediates for preparing the compounds according to the invention, pharmaceutical compositions comprising the compounds according to the invention and their prophylactic and therapeutic use for hyperproliferative disorders, in particular for tumor disorders. Also described is the use of BET protein inhibitors for benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, for neurodegenerative disorders, for inflammatory disorders, for atherosclerotic disorders and for the control of male fertility.

Abstract: Sealing connectors for use in connecting tubing to tubing, tubing to needles or other implements, syringe to tubing, or syringe to needles or other implements that provide reduced turbulence and sharp transitions are described herein.

Abstract: The disclosure provides for compositions and including fluopyram. The disclosure further provides for methods of increasing plant yield and reducing plant damage. Soil, seeds, plants, and plant parts treated with compositions described herein are also provided for by the disclosure.

Abstract: A process for preparing N-[(6-chloropyridin-3-yl)methyl]-2,2-difluoroethan-1-amine of formula (III) wherein 2,2-difluoroethylamine of formula (I) is reacted with a halide of formula (II) in the presence of a hydroxide of an alkali metal or alkaline earth metal.

Abstract: The present application relates to novel substituted pyrazolo[1,5-a]pyridine-3-carboxamides, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.

Abstract: The present invention pertains to a pharmaceutical composition comprising the compound of the formula (I) in a high concentration and at least one pharmaceutically acceptable excipient, the use of the composition for the treatment of hyper-proliforative diseases, such as cancer, either as a sole agent, or in combination with other anti-cancer therapies, and the process for preparing of said composition.

Abstract: The present invention relates to a composition comprising a biologically pure culture of a fungicidal Paenibacillus sp. strain comprising a variant fusaricidin synthetase lacking a functional adenylation domain in the third module. The present invention also provides a composition comprising a biologically pure culture of a fungicidal Paenibacillus sp. strain or a cell-free extract thereof comprising at least one Paeniserine and at least one Paeniprolixin. Also provided are isolated compounds and methods of treating a plant to control a plant disease with the disclosed compositions and compounds.

Abstract: The present invention relates to fluorinated benzofuranyl-pyrimidine derivatives containing a sulfoximine group of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).

Abstract: The present invention relates to amido-substituted azole compounds of general formula (I), in which X1, X2, R1, R2, R4, R5, R7 and R8 are as defined in the claims which are inhibitors of TNKS1 and/or TNKS2, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.